Opinion|Videos|July 10, 2024
Key Findings from the NADINA Trial at ASCO 2024
Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the data presented at the 2024 ASCO Annual Meeting on the phase 3 NADINA trial (NCT04949113) of neoadjuvant nivolumab plus ipilimumab vs adjuvant nivolumab in patients with macroscopic, resectable stage III melanoma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study. How might these findings impact the treatment of patients with melanoma?
- What are the key considerations when deciding between neoadjuvant and adjuvant therapy for patients with resectable melanoma?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
2
FDA Approves Another OTC Naloxone Nasal Spray for Opioid Overdose
3
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
4
United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF
5